DHR · Danaher

The thesis

Danaher's shares have a modest edge over the S&P 500 because bioprocessing orders are rising faster than revenue. Those orders should reach sales during 2027. Formal 2027 guidance with the fourth-quarter report, expected in late January 2027, settles the case. It shows whether growth meets or beats management's starting point of 4% to 5% core growth, which is sales growth excluding acquisitions and currency effects. The rating is Medium because the order evidence is real but revenue has missed it before.

Chief Executive Julie Sawyer Montgomery repeated the 4% to 5% starting point for 2027 at the UBS Global Healthcare Conference on 9 November 2026, according to Investing.com's account of the session. She said Cytiva equipment orders grew by a mid-teens percentage in the third quarter. Orders take about 9 to 12 months to turn into revenue, which puts the conversion inside 2027. She also sized U.S. manufacturing reshoring at about $1 billion of extra demand, mostly bioprocessing equipment, with revenue mainly in 2028 and later.

The price already reflects a recovery. Trefis put Danaher's market value at $160 billion at the 2 November 2026 close, or 26.4 times fiscal 2026 profit. The shares closed at $235.31 on 11 November 2026, 3.1% below the 52-week high of $242.80 set on 22 January 2026. At that multiple, 2027 guidance at the 4% to 5% starting point holds the case up but adds little to it. Guidance above that range is what would carry the shares ahead of the index.

Bullish and bearish views on Danaher Corporation

The bull case on Danaher Corporation (DHR), in brief: third quarter beat with wider margins. The bear case: strong orders have missed on revenue before.

Bull case

• Third quarter beat with wider margins. Sales were $6,554 million in the third quarter, up 8.5%, according to the company's 21 October 2026 8-K. Adjusted earnings per share (EPS) rose 11.5% to $2.11, ahead of the $1.92 FactSet consensus reported by Dow Jones.
• Orders running ahead of revenue. Management said on 21 October 2026, and again on 9 November 2026, that bioprocessing orders rose by a mid-teens percentage in the third quarter. Biotechnology segment core sales grew 5.0%, per the 8-K. Cytiva is about 30% of the company, per the 9 November 2026 UBS session.
• Full-year guidance raised. On 21 October 2026 the 2026 adjusted EPS range moved to $8.57–$8.62 from $8.45–$8.60. The fourth-quarter outlook calls for 4.0% to 5.0% core growth excluding respiratory testing.
• A smaller supplier reports similar demand. Repligen, which also sells bioprocessing products, reported third-quarter revenue of $209.3 million on 27 October 2026, up 12.5% organically, per its 8-K. It raised its 2026 revenue outlook to $844 million to $852 million, a range that includes its BioLife acquisition.
• Diagnostics products keep clearing regulators. Cepheid's Xpert Respiratory Panel, which detects 13 respiratory pathogens, received European CE marking under the In Vitro Diagnostic Regulation on 10 November 2026. Two U.S. Food and Drug Administration (FDA) clearances followed on 3 November 2026, for Cepheid's hemorrhagic fever panel and Beckman Coulter's MeMed BV assay. Management said on 9 November 2026 that it expects Cepheid to grow by double digits excluding respiratory testing.
• Most broker targets sit above the price. Goldman Sachs moved its target to $275 on 22 October 2026. Citi, JPMorgan and TD Cowen moved theirs to $270, and HSBC moved to $260 on 23 October 2026. Investing.com showed an average target of $259.90 on 6 November 2026, with 20 of 24 analysts rating the shares positively.

Bear case

• Strong orders have missed on revenue before. Reuters reported on 21 July 2026 that second-quarter biotechnology revenue of $1.92 billion fell short of the $1.97 billion LSEG estimate. Management blamed customer project timing, in a quarter when orders were also strong.
• Respiratory testing still drags growth. Diagnostics core sales grew only 0.5% in the third quarter, per the 21 October 2026 8-K. Total core growth was 3.0%, against 5.5% excluding respiratory testing. On 21 July 2026 the company cut the top of its 2026 core growth range to 4% from 6% on weaker respiratory revenue, per Reuters.
• Reshoring revenue is further out. Management placed most revenue from the roughly $1 billion reshoring opportunity in 2028 and later, at the 9 November 2026 UBS session. It helps the long-term growth goal more than the 2027 plan.
• Two broker targets sit below the price. Evercore ISI cut its target to $205 from $242 on 28 October 2026. Rothschild & Co Redburn raised its target to $220 from $205 on 26 October 2026. Both sit below the $235.31 close on 11 November 2026. DZ Bank downgraded the shares to hold on 27 October 2026, per Investing.com.
• Officers keep selling near $235. SEC Form 4 filings show EVP Matthew McGrew exercised options and sold 17,385 shares at $235.69 on 9 November 2026, after selling 29,754 shares at an average $235.74 on 28 October 2026. EVP Gregory Milosevich sold 2,100 shares at $230.62 on 9 November 2026. Chief Accounting Officer Christopher Bouda sold 7,598 shares at an average $234.56 on 28 October 2026.

Price setup

The shares closed at $235.31 on 11 November 2026. That is 3.1% below the 52-week high of $242.80, an intraday level from 22 January 2026. The 52-week closing low was $161.91 on 15 May 2026. Adjusted daily closes show a 15.6% gain over three months from the 13 August 2026 reference close of $203.89.

Most of that gain came in the reaction to the 21 October 2026 report. Daily closes from 4 November to 11 November 2026 ranged from $226.34 on 5 November 2026 to $236.11 on 10 November 2026. The officer sales on 28 October 2026 and 9 November 2026 were near the top of that range.

The last close sits above the 50-day moving average of $221.48 and the 200-day moving average of $200.30, both as of 11 November 2026. A move through the January high of $242.80 would take the shares to a new 52-week high. The 50-day average is the nearest level below that measures the post-earnings trend. Rothschild & Co Redburn's $220 target sits just below it.

Catalysts ahead

• 17 November 2026: CEO presentation at the Jefferies Global Healthcare Conference, London, 10:00 a.m. GMT. A second public check after the 9 November 2026 UBS session on bioprocessing order trends, customer timing and the 4%–5% 2027 starting point.
• ~12 January 2027 (est.): J.P. Morgan Healthcare Conference presentation. Management commentary there could give a first read on 2027 growth and bioprocessing demand ahead of formal guidance.
• ~27 January 2027 (est.): Q4 2026 report and formal 2027 guidance. Shows whether 2027 core growth excluding respiratory testing is guided at or above the 4%–5% starting point, and whether third-quarter orders are turning into revenue.

What would change the view

A daily close below $210, which would put the shares under Rothschild & Co Redburn's $220 target and near Evercore ISI's $205. Formal 2027 guidance in January for core growth excluding respiratory testing below 4% would also show the call is wrong.

The risks this note tracks, each with what would confirm it:

• Bioprocessing customers delay shipments again and push revenue into later periods, as customer project timing did in Q2 2026. Confirmed by: management naming new customer deferrals, or orders slowing from the mid-teens rate, at the 17 November 2026 Jefferies conference or the January report.
• Respiratory testing revenue falls further and keeps holding back Diagnostics growth. Confirmed by: Diagnostics core growth turning negative in the fourth quarter, or a lower 2027 respiratory revenue plan in January.
• Broker caution spreads and insiders keep selling into the post-earnings gain. Confirmed by: more brokers following Evercore ISI's 28 October 2026 cut to $205, or further officer sales filed on SEC Form 4.
• The new chief executive sets a cautious first 2027 plan that resets expectations lower. Confirmed by: January guidance framed around execution fixes, with core growth excluding respiratory testing below the 4%–5% starting point.

What it trades with

Danaher trades with the life-science tools and bioprocessing suppliers. Repligen's 27 October 2026 report pointed in the same direction as Danaher's, so news from one supplier tends to reprice the group. Biopharma customer spending on drug manufacturing drives this part of the case.

The Diagnostics segment ties Danaher to respiratory testing seasons through Cepheid. That links it to diagnostics peers more than to device makers. Masimo, acquired on 10 June 2026, grew by a high-single-digit rate in the third quarter, per management on 9 November 2026, which adds some exposure to hospital device spending. A broad pullback in healthcare shares would still weigh on the stock.